Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,772 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06265727RecruitingPhase 1/Phase 2
Study of CRB-701 for solid tumors with nectin-4
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
Birmingham, AlabamaAges 18 years+ - NCT06245122RecruitingPhase 1
Study of CS23546 for advanced tumors
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
GuangzhouAges 18 years+ - NCT06249282RecruitingPhase 1
Carfilzomib and sotorasib for KRAS G12C lung cancer
This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.
Duarte, CaliforniaAges 18 years+ - NCT06246968RecruitingPhase 1
Pembrolizumab plus tumor ablation for advanced triple-negative breast cancer
This study tests combining an immunotherapy drug (pembrolizumab, also called Keytruda) with a procedure that freezes or destroys cancer cells directly (called ablation). The goal is to see if this combination can help control triple-negative breast cancer that has spread or is inoperable.
Basking Ridge, New JerseyAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT06150885RecruitingPhase 1/Phase 2
An immune cell therapy for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR gamma-delta T cells) for advanced solid tumors that have not responded to standard treatments. The therapy uses donor cells that are specially trained to find and attack cancer cells.
Taichung, Non-USAges 18 years+ - NCT06127407RecruitingPhase 3
Ivosidenib for advanced chondrosarcoma with IDH1 mutation
This trial tests an experimental drug called ivosidenib for people with a specific type of bone cancer (chondrosarcoma) that has spread or can't be removed with surgery. The drug targets a genetic change (IDH1 mutation) found in some chondrosarcomas. It may help slow or stop tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06062498RecruitingPhase 2
Elacestrant alone or with a CDK4/6 inhibitor for advanced breast cancer
This trial compares a new hormone therapy (elacestrant) to the same therapy combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) for people with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has a mutation in the ESR1 gene. It aims to see if the combination works better than the single drug.
Chicago, IllinoisAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06028074RecruitingPhase 1/Phase 2
Study of GIM-122 for advanced solid tumors
This trial tests a new drug, GIM-122, in people with advanced solid tumors that have stopped responding to or cannot tolerate standard PD-1/PD-L1 inhibitors. The goal is to see if GIM-122 is safe and tolerable.
Los Angeles, CaliforniaAges 18 years+ - NCT06008288RecruitingPhase 2
JAB-21822 for advanced pancreatic or other solid tumors with KRAS G12C
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
Hefei, AnhuiAges 18 years+ - NCT06010342RecruitingPhase 2
TL118 for solid tumors with NTRK fusion
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
Glendale, CaliforniaAges 18 years+ - NCT05522868RecruitingPhase 1
Tested drug for solid tumors after standard treatment stopped
This Phase 1 study tests SB17170 in people with solid tumors that have spread or grown despite standard treatments. It looks for safety and early signs of how well the drug might work when other options have failed.
SeoulAges 19 years+ - NCT05958121RecruitingPhase 1/Phase 2
IMA402 immune therapy for advanced solid tumors
This trial tests an immune system treatment (IMA402) that is meant to help the body recognize and fight advanced solid tumors. It may be an option if your cancer has come back or did not respond to standard treatments, and if your overall health and tumor measurements meet study requirements.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05903833RecruitingPhase 2
Study pembrolizumab and lenvatinib for advanced vulvar cancer
This trial tests whether combining pembrolizumab with lenvatinib can shrink and control advanced vulvar squamous cell cancer that can’t be fully treated with surgery or strong radiation. It may help some people live longer and better control symptoms, but it also requires close monitoring and specific health criteria.
AugsburgAges 18 years+ - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05860465RecruitingPhase 2/Phase 3
Tested blood cancer medicine with hormone therapy for breast cancer
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
Guangzhou, GuangdongAges 18–75 - NCT05800665RecruitingPhase 1
Study tests a new prostate cancer drug after prior hormone therapy
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
Scottsdale, ArizonaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05718895RecruitingPhase 1
ATG-022 for advanced solid tumors that have stopped responding
This early-phase study tests ATG-022 in adults with advanced or metastatic solid cancers that have progressed on standard treatment, cannot use standard treatment, or have no standard option. It may help by targeting cancer cells differently, and participation includes close monitoring and likely a biopsy.
AdelaideAges 18 years+ - NCT05701527RecruitingPhase 1
EBC-129 for advanced solid tumors with limited treatment options
This Phase 1 study tests EBC-129, a new investigational treatment, in people with advanced solid tumors that cannot be fully removed and have limited or no good standard treatment options. The goal is to learn if the treatment is safe, find helpful dosing, and see signs it may slow the cancer.
Aurora, ColoradoAges 18 years+ - NCT05098184RecruitingEarly Phase 1
Study TIL treatment for advanced melanoma using harvested tumor cells
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
ShanghaiAges 18–75 - NCT05098171RecruitingEarly Phase 1
Study TIL cell therapy for advanced gynecologic cancers
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
La Jolla, CaliforniaAges 18–130
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,772 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.